Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Suramin

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PaxMedica To Provide Immediate PAX-101 IV Suramin Access
    PaxMedica To Provide Immediate PAX-101 IV Suramin Access

    23 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/23/2867666/0/en/PaxMedica-Responds-to-Emergency-Request-for-IV-Suramin-and-Commits-to-Provide-Immediate-Access-to-PAX-101.html

    GLOBENEWSWIRE
    23 Apr 2024
    Share Share
    PaxMedica Receives Emergency IV Suramin Request from African Health Ministry
    PaxMedica Receives Emergency IV Suramin Request from African Health Ministry

    16 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/16/2864119/0/en/PaxMedica-Receives-Emergency-Request-for-IV-Suramin-from-African-Health-Ministry-for-Use-in-Treating-Fatal-Sleeping-Sickness.html

    GLOBENEWSWIRE
    16 Apr 2024
    Share Share
    SAHPRA grants approval to begin trial of PaxMedica’s long Covid-19 therapy
    SAHPRA grants approval to begin trial of PaxMedica’s long Covid-19 therapy

    10 Jan 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/sahpra-paxmedica-covid-trial/

    CLINICALTRIALSARENA
    10 Jan 2022
    Share Share
    PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in COVID-19 Syndrome
    PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in COVID-19 Syndrome

    07 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/paxmedica-plans-to-initiate-phase-1b-study-for-pax-101-in-patients-with-long-covid-19-syndrome-301456006.html

    PRNEWSWIRE
    07 Jan 2022
    Share Share
    IV suramin may be a promising autism treatment, shows Phase II study
    IV suramin may be a promising autism treatment, shows Phase II study

    29 Oct 2021

    // Anna Begley EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/164740/iv-suramin-may-be-a-promising-autism-treatment-shows-phase-ii-study/

    Anna Begley EUROPEANPHARMACEUTICALREVIEW
    29 Oct 2021
    Share Share